Show/hide main menu

News

News Highlights

Project launch: Remote Assessment of Disease and Relapse - Alzheimer's Disease

Posted on 13/02/2019

Remote-Assessment-Disease-and-Relapse-Alzheimers-Disease-430x275

Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) is now underway, applying, amongst others, the techniques and technologies developed under RADAR-CNS to assess progression of patients with early Alzheimer’s Disease.

RADAR-AD will draw on a wealth of lessons and expertise from people active in the RADAR-CNS and other projects in developing remote measuring technology to be used by patients with early Alzheimer’s.

Like RADAR-CNS, which looks at diagnoses linked to the central nervous system, RADAR-AD is a Public Private Partnership funded by the Innovative Medicines Initiative, with representation from academic institutions, small-to-medium enterprises, public organisations and pharmaceutical companies. Professor Dag Aarsland, Chair of Old Age Psychiatry at the IoPPN is leading the project together with Vaibhav Narayan from Janssen Pharmaceutica. 

The team will seek solutions that take account of particular characteristics shared by many people with Alzheimer’s: many are older and may not have had much exposure to technology, and their condition may also make it more difficult for them to learn to handle technical devices. A key aim of the project is to find ways to measure any reduction in ability to live and function independently early on in the course of an individual’s condition.

Professor Aarsland commented: ‘There is more and more interest in the use of widely available and affordable digital technology to improve outcomes for people with Alzheimer’s. Our hope is that RADAR-AD will result in clinical and technological advancements so that valuable new treatments can be identified and implemented. People with Alzheimer’s Disease will be fundamentally involved in the design and development of the project so that the solutions we generate are acceptable and appropriate for people in their everyday lives.’

Contact

For further media information please contact: Amy Edmunds, Communications and Engagement Manager, NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, amy.edmunds@kcl.ac.uk / 020 7848 0495 or 07500 224 906

News Highlights:

News Highlights...RSS FeedAtom Feed

E-cigarette use plateaus among British smokers

E-cigarette use plateaus among British smokers

Description
An independent report, led by researchers at the National Addiction Centre at the IoPPN and commissioned by Public Health England (PHE), finds regular e-cigarette use among British adults has plateaued...
Categories:
Press Release
Troubling extent of trauma and PTSD in young people revealed

Troubling extent of trauma and PTSD in young people revealed

Description
New research from King's College London suggests one in 13 young people in the UK have had post-traumatic stress disorder (PTSD) before reaching age 18.
Categories:
Press Release
Cannabis-based medicine to be tested in Alzheimer's trial

Cannabis-based medicine to be tested in Alzheimer's trial

Description
Researchers from the NIHR Maudsley BRC are to lead a pioneering new study into a cannabis-based treatment for people living with dementia.
Categories:
Press Release
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2019 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454